QuantHealth secured $45 million in Series B funding to expand its AI platform that simulates clinical trials before patients enroll. The company’s approach aims to predict patient outcomes and trial performance to help pharma teams refine study design earlier, targeting reductions in the high trial-failure rate and accelerating timelines. The startup said its simulation capabilities are designed to model how specific cohorts and interventions perform under realistic conditions, moving decision-making upstream in development. QuantHealth positions the platform as a way to validate assumptions—such as eligibility criteria and endpoint behavior—before expensive enrollment begins. The financing underscores sustained capital interest in computational tools for clinical development optimization, especially as sponsors demand faster, evidence-backed readouts in crowded oncology pipelines.